Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?
1. LYRA's LYR-210 showed significant CRS symptom improvement in Phase 3 trials. 2. Trial results indicated improved scores at week 24, beginning by week 4. 3. Safety profile of LYR-210 remained favorable, similar to sham control. 4. LYRA stock surged 411.6% to $25.22 after positive trial outcomes. 5. ENLIGHTEN 1 trial faced failures, contrasting with ENLIGHTEN 2 successes.